Home
RNA Therapeutics
22 February - 23 February 2017
RNA Therapeutics

“RNA therapeutics, including recent exciting advancements in RNA-based vaccines, have the potential to be game-changing technologies. This conference will bring together thought leaders from across the technology area and a great opportunity to cross fertilize”
– Jeffrey Ulmer, Head of Preclinical Research & Development, GSK


EVENT HIGHLIGHTS:

Attendees from across the world. Nations confirmed to attend include:

Australia, Belgium, Denmark, Germany, Ireland, Israel, Italy, Japan, Netherlands, Switzerland, Ukraine, United Kingdom and USA.
The attendee list can be viewed in the download centre.

MHRA Keynote Address: Don't miss our exclusive MHRA keynote on RNAi therapy regulations. As well as providing a detailed overview of the regulatory landscape, the talk given by John Johnston, Clinical Assessor in the Biologicals and Biotechnology Unit, will offer guidance on requirements and reporting clinical data.

Over 17 presentations from a mix of leading industry players and scientific pioneers such as Imperial College London, GSK, AstraZeneca, Novartis, Roche, BioNTech AG, Silence Seed, Quark Pharmaceuticals, Exicure and more.

Download a brochure to take a look at the full conference programme and speaker line up for 2017.

Pre-conference interactive workshop carefully selected to bring you hands on training and complement the topics covered in the conference agenda.

The need for functional delivery of RNAi effectors to target cells is a primary problem that is holding back the field of RNAi therapeutics. Nanoparticles, molecular conjugates, and other delivery technologies have their place but are they really working well enough? If not why not? And if they do appear to be working, what will it actually take to realise clinical success?

Hosted by Andrew Miller, Professor of Organic Chemistry & Chemical Biology at Imperial College London, the workshop on Precision Nano-Therapeutics: Minding The Gap In Delivery From Preclinical Studies To Clinical Success, will help attendees appreciate the magnitude of the gap that must be bridged between academic-preclinical studies and the needs of the pharma industrial for success in RNAi therapeutics.
 

This is your last chance to register.

We look forward to welcoming you to an engaging and insightful event!

FEATURED SPEAKERS

Heinrich Haas

Heinrich Haas

VP RNA Formulation and Drug Developement , BioNTech AG
John Johnston

John Johnston

Clinical Assessor, Biologicals & Biotechnology Unit, MHRA
Nicole meisner-kober

Nicole meisner-kober

Senior Investigator, Novartis Institutes for Biomedical Research
Steffen Panzner

Steffen Panzner

Managing Director, Lipocalyx
Steve Hood

Steve Hood

Director, Scinovo, GSK

Amotz Shemi

CEO, Silenseed
Amotz Shemi

Dr. Amotz Shemi is the Chief Executive Officer and a co-founder in Silenseed. Prior to Silenseed, Dr. Shemi served as a Senior VP Technologies in Medinol LTD, a leading medical-stent company for cardiovascular and gastroenterology diseases, and beforehand as the CEO of Color Chip, a leader in Ion-exchange based Planar Lightwave Circuits (PLC); Dr. Shemi brings with him 25 years of experience in end-to-end management from concept level via development, regulatory approvals to actual sales. Shemi received his PhD degree in Physics and Astrophysics from the Tel Aviv University in Israel. Dr. Shemi is a lead inventor of more than dozen patents in the RNAi-delivery field, and an author and co-author of about 40 scientific papers.

Andreas Kuhn

Vice President RNA Biochemistry & Manufacturing, BioNTech
Andreas Kuhn

Andreas Kuhn, Ph.D., has worked in the field of RNA biochemistry and molecular biology for more than twenty years. His work on RNA-based immunotherapies began in 2007, and Andreas joined BioNTech RNA Pharmaceuticals GmbH (formerly Ribological GmbH) shortly after its founding. His main focus is expanding Ribological® proprietary technologies to increase the efficacy of RNA immunotherapies and to optimize GMP-compatible manufacturing processes for RNA. He has co-authored several publications and patents ranging from basic research on RNA to its application as a diagnostic and therapeutic agent.

Andrew Miller

CSO, KP Therapeutics Ltd
Andrew Miller

Prof Miller is a leading chemist expert in the understanding and exploitation of molecular mechanisms in biology. The overall goal of his academic research has been and continues to be the design and creation of advanced therapeutics and diagnostics that address unmet medical need in the management of chronic diseases. From 1990-2010, Prof Miller was a member of academic staff in the Chemistry Department of Imperial College London (UK) where he became full Professor of Organic Chemistry & Chemical Biology in 2002, plus founding Director of the Imperial College Genetic Therapies Centre from 1998. Since 2010, Prof Miller has been based at King’s College London from where he has been developing his career as an academic entrepreneur, this year founding KP Therapeutics Ltd. The company’s Bio-Nano pipeline of potential products in discovery & development all derives from the best of Prof Miller’s personal and collaborative academic research work over the past two decades, involving a research spend of at least £20 million.

Andrew Miller

CSO, KP Therapeutics Ltd
Andrew Miller

David Giljohann

CEO, Exicure Inc.
David Giljohann

David Giljohann is the CEO of Exicure, Inc., a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin at Northwestern University where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and spherical nucleic acid constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition.

Heinrich Haas

VP RNA Formulation and Drug Developement , BioNTech AG
Heinrich Haas

Heinrich Haas, Ph.D. has more than 18 years of experience in academic research and industrial pharmaceutical development. After he received his Ph.D. in physical chemistry, he researched lipid membranes and organized biomolecular systems.

His professional focus is on colloidal/nanoparticulate formulations for targeted drug delivery with therapeutic and diagnostic applications. Before joining BioNTech RNA Pharmaceuticals GmbH (former Ribological GmbH), he was responsible for a variety of projects in biopharmaceutical research and development, ranging from the exploration of novel colloidal therapeutic and diagnostic carriers to up-scaling and development of market-compliant manufacturing methods for liposome products. After joining BioNTech RNA Pharmaceuticals GmbH in 2010, he helped build the formulation development and analytics unit, which develops formulations for delivery of RNA and small molecules. Heinrich is also the Head of IMP manufacturing at BioNTech RNA Pharmaceuticals GmbH. He has an active record of publications in peer-reviewed journals (30+) and patent applications (10+) in the field of drug delivery.

Jeffrey Ulmer

Head Preclinical R&D, GSK
Jeffrey Ulmer

Dr. Jeffrey Ulmer received his B.Sc. with honours from the Department of Chemistry at the University of Regina in 1978 and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University in 1985 and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories, Chiron Corporation and Novartis Vaccines he conducted seminal studies on nucleic acid vaccines and novel vaccine adjuvants/delivery systems. He has published over 200 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy, Human Vaccines, and Expert Review of Vaccines. He is currently Head, Preclinical R&D, GSK Vaccines.

John Johnston

Clinical Assessor, Biologicals & Biotechnology Unit, MHRA
John Johnston

Maj Hedtjärn

Head of Drug Discovery, RNA Therapeutics Research, Roche
Maj  Hedtjärn

Mark Chapman

Partner, Carpmaels & Ransford
Mark  Chapman

Mark is an experienced specialist Biotech patent attorney, based at Carpmaels & Ransford (a European IP firm) in London. Mark’s career as a patent attorney spans 15 years, ever since studying Molecular & Cellular Biochemistry at Oxford University, and graduating in 2001. During this time his practice has focused heavily on assisting companies developing nucleic acid therapeutics and diagnostics. Mark’s work in recent years has included the patent protection in Europe and elsewhere of Mipomersen (Kynamro®), Nusinersen and Volanesorsen (all Ionis Pharmaceuticals-developed antisense oligonucleotide therapeutics), along with the protection of numerous other candidate therapeutics for Ionis Pharmaceuticals. Mark also works closely with Regulus Therapeutics, for example prosecuting and defending European patents in Stanford University’s ‘Sarnow’ patent estate (relating to the use of miR-122 inhibitors for HCV treatment) for Regulus as licensee. Mark’s recent experience also includes prosecuting and defending European patents in Stanford University’s ‘Quake’ patent estate (relating to NIPT methods based on cffDNA in maternal blood) for licensee client Verinata Health (Illumina). Mark has also prepared and filed numerous successful oppositions to third party patent applications and patents, working to secure freedom to operate for his innovator clients.

Mark Edbrooke

Senior Principal Scientist, AstraZeneca
Mark Edbrooke

Mark Edbrooke earned his PhD in molecular biology from the University of London. He ran a transnational Gene Interference functional genomics department at GSK that generated target identification and validation data for all therapeutic areas across the company (e.g. oncology, cardiovascular, respiratory, neurology and infectious diseases). He then founded and led a Discovery Performance Unit (DPU) within GSK focused on the development of therapeutic siRNAs and, latterly, on therapeutic antisense oligonucleotides. He recently joined AstraZeneca (AZ) and is involved in AZ’s alliances with Ionis Pharmaceuticals, Regulus Therapeutics, and Moderna Therapeutics.

 

Nagy Habib

Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
Nagy Habib

Professor Nagy Habib is Head of HPB Surgery at the Hammersmith Campus of Imperial College London and also a serial founder and entrepreneur of life sciences ventures. He is co-founder of several biotech companies: EMcision Ltd, OmniCyte Ltd, MiNA Therapeutics Ltd, Apterna Ltd, Medeva Plc and Bioenvision Ltd. Previously he was Pro-Rector for Commercial Affairs at Imperial College London.
 

He is a translational researcher who pioneered the first clinical trial of the use of plasmid and adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He was the Principal Investigator of world first clinical trials published on the use of adult bone marrow-derived stem cells for the treatment of patients with liver insufficiency and CD34+ cells for patients with stroke.
He was the inventor and co-author on the first publication to describe the use of radiofrequency energy in devices for liver surgery (Habib 4X), and interventional endoscopy (Habib™ EndoHPB and Habib™ EUS-RFA).
 

Professor Habib holds a gold award from the Advisory Committee for Clinical Excellence which is given to recognise and reward the exceptional contribution of NHS consultants, over and above that normally expected in a job, to the values and goals of the NHS and to patient care, and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine.
In the 2014 Research Excellence Frame work (REF) exercise, which is the system for assessing the quality of research in UK in higher education institutions, Professor Habib was rated as a 4* researcher which is the highest ranking. His work on radiofrequency ablation was selected among those that have had the most “Impact on Society” and was ranked 1 with a score of 93%. In January 2015 he was elected as a Foreign Member by the prestigious French Académie Nationale de Chirurgie.
 

Nicole meisner-kober

Senior Investigator, Novartis Institutes for Biomedical Research
Nicole meisner-kober

Sanyogitta Puri

Associate Prinicipal Scientist, AstraZeneca
Sanyogitta Puri

Shai Erlich

VP, Pharmaceutical Development, Quark Biotech Inc
Shai Erlich

Shai Erlich is the President of Quark USA Operations and Chief Medical Officer. Dr. Erlich joined Quark in 1999 and since then has assumed several executive positions including Director of Portfolio Management,Product Development Strategic Planning and Vice president for Pharmaceutical Development . Dr. Erlich completed his studies at the School of Medicine at Ben Gurion University in Israel, and holds an M.Sc. in cancer genetics from the department of Human Genetics, Tel Aviv University, and a Ph.D. in Gene Therapy from the Department of Human Genetics, Mt Sinai Graduate School for Biomedical Sciences at the Mt. Sinai School of Medicine, New York.

Steffen Panzner

Managing Director, Lipocalyx
Steffen Panzner

Dr. Panzner is an expert in oligonucleotide delivery; author of more than 35 patent families and numerous scientific publications covering novel concepts for oligonucleotide delivery such as the Viromer® (virus-mimicking polymer) and the Smarticles® (amphoteric liposome) technology. Products based on these technologies are in phase 2 clinical trials or earlier stages of development.
 

Dr. Panzner was Founder and CSO of Novosom AG between 1999 and 2010 and is Founder and CEO of Lipocalyx GmbH which started 2011. He also is a consultant and CMC expert for pharma and biotech companies as well as for VC firms.
 

Steve Hood

Director, Scinovo, GSK
Steve Hood

Steve studied for his PhD in Molecular Toxicology at Surrey University and joined Glaxo Group Research as a Post-Doctoral Fellow in 1993. Following the formation of GSK in 2001, Steve managed a team determining the drug-drug interaction liabilities while developing ADME strategies for the emerging GSK antibody portfolio.
In 2010, Steve led a cross divisional team charged with understanding and overcoming the delivery issues inherent in GSK’s diverse oligo portfolio while helping to develop these molecules from earlt discovery to file. In 2011 Steve initiated the project that has grown into the IMI COMPACT collaboration and he is actively involved in facilitating the interaction between academia , biotech and large industry partners.
Finally, for the past couple of years, Steve has been responsible for helping GSK Programme teams answer the fundamental questions of “Where does my drug go and what does it do when it gets there?” using a range of Bioimaging methodologies.
 

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

clock

9:10

RNA activation and its clinical application

Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

  • Small activating RNA (saRNA) can activate most of the coding and non-coding genome
  • CEBPa is a transcriptional activation of the hepatocyte that can be upregulated with saRNA
  • Clinical application: SARNA CEBPa offers a therapeutic opportunity for patients with NASH and liver failure
  • clock

    9:50

    Collaborating to deliver macromolecules across biological barriers – a review of IMI COMPACT

    Steve Hood, Director, Scinovo, GSK

  • What are the challenges of Oligo Delivery?
  • How do we optimise delivery
  • Who are COMPACT and what have we achieved?
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Delivery of mRNA using the Viromer® system

    Steffen Panzner, Managing Director, Lipocalyx

  • A lesson learned from a virus: the Viromer delivery system
  • Formulation aspects of Viromer nanoparticles
  • Viromer: mRNA delivery on multiple routes
  • clock

    11:40

    Therapeutic antisense oligonucleotides in oncology

    Mark Edbrooke, Senior Principal Scientist, AstraZeneca

  • The progress of emerging antisense oligonucleotide drugs and the targeting of un-druggable sites in oncology
  • Methods in drug delivery
  • Update on clinical trials in the field
  • clock

    12:20

    Networking Lunch

    clock

    13:30

    RNA therapeutics harnessing the potential of locked nucleic acids

    Maj  Hedtjärn

    Maj Hedtjärn, Head of Drug Discovery, RNA Therapeutics Research, Roche

  • Exciting new insights into RNA Therapeutics drug discovery
  • Locked Nucleic acids: an update on how they are drug candidates for diseases with difficult targets
  • Next generation drugs and how they are transforming the treatment of diseases
  • New concepts to conducting drug discovery and optimising the process
  • clock

    14:10

    Sites of RNA silencing: Cell entry of exosomes as a novel paradigm for therapeutic RNA delivery

    Nicole meisner-kober

    Nicole meisner-kober, Senior Investigator, Novartis Institutes for Biomedical Research

  • Recent data on how exosomes have evolved a specific route for cell entry
  • Improvements in subcellular targeting to directly improve the therapeutic index and thus the clinical viability of siRNA therapies
  • The inefficiencies of some liposomal delivery vehicles in delivering siRNA to the endoplasmic reticulum
  • Next generation RNA delivery vehicles- models to enhance the targeting of translation and RNA silencing sites
     
  • clock

    14:50

    Afternoon Tea

    clock

    15:20

    RNAi and tumor microenvironment: pre-clinical and clinical evidence

    Amotz Shemi, CEO, Silenseed

  • The case of silencing mutated KRAS
  • Prolonged drug release continuously affects the tumor microenvironment
  • RNAi and immunotherapy
     
  • clock

    16:00

    Individualized mRNA-based cancer immunotherapy

    Andreas Kuhn, Vice President RNA Biochemistry & Manufacturing, BioNTech

  • Regulatory framework for mRNA-based therapeutics
  • Optimisation of mRNA for therapeutic application
  • GMP manufacturing of mRNA
  • The IVAC MUTANOME concept
  • First clinical experience with mRNAs in individualised
    cancer immunotherapy
  • clock

    16:40

    Chairman’s Closing Remarks and Close of Day One

    Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech AG

    clock

    9:10

    Interacting with the medicines regulator on RNAi therapies

    John Johnston

    John Johnston, Clinical Assessor, Biologicals & Biotechnology Unit, MHRA

  • A brief description of the regulatory environment
  • How to interact with the regulator
  • Some thoughts on reporting clinical data
  • clock

    9:50

    Nano-therapeutics; the best of all possible worlds?

    Andrew Miller, CSO, KP Therapeutics Ltd

     

     

     

  • New delivery systems for RNAi effectors usually result from horizontal not vertical developments
  • The need for vertical developments in nanoparticle mediated RNAi effector delivery
  • A rational framework for vertical developments
  • The potential power of Image guidance in nanoparticle mediated RNAi effector delivery
     
  • clock

    10:30

    Morning Coffee

    clock

    11:40

    Intravenously injectable RNA Nanomedicines as cancer vaccines: case study with RNA-Lipoplexes

    Heinrich Haas, VP RNA Formulation and Drug Developement , BioNTech AG

  • Proceedings in development of nucleic acid based nanomedicines
  • RNA delivery technologies: challenges and opportunities
  • mRNA for cancer vaccination
  • Formulation development and preclinical proof-of concept for RNA-lipoplex formulations
  • GMP manufacturing and clinical testing of RNA-lipoplex products
  • clock

    12:20

    Networking Lunch

    clock

    13:30

    The challenges and lessons learnt about the delivery of small and large nucleic acids to cancers

    Sanyogitta Puri

    Sanyogitta Puri, Associate Prinicipal Scientist, AstraZeneca

  • Formulation of siRNA vs plasmid
  • mRNA delivery to tumours
  • Identification of key quality attributes and correlation to in vitro/in vivo effi cacy
  • Key challenges for development and manufacturing therapeutics
  • clock

    14:10

    Protecting the kidney: using siRNA targeting p53 to prevent and ameliorate acute kidney injury and delayed graft functio

    Shai Erlich, VP, Pharmaceutical Development, Quark Biotech Inc

  • Taking advantage of the natural distribution of siRNA to renal tissue
  • The therapeutic approach of temporary p53 inhibition to prevent acute tissue damage
  • Challenges encountered along the journey to phase III clinical trials
  • Detailed results from a large Phase II clinical trial aimed at prevention of Delayed Graft Function in patient receiving kidney transplant from deceased donors
  • clock

    14:50

    Afternoon Tea

    clock

    15:20

    Spherical Nucleic Acids:Structures for topical gene regulation

    David Giljohann, CEO, Exicure Inc.

  • Spherical Nucleic Acids (SNAs) are Three-dimensional arrangements of nucleic acids
  • SNAs effectively enter cells and tissues through Scavenger Receptors
  • Local, topical application of SNAs have allowed for early clinical trials
  • A Phase I microplaque study in patients with psoriasis was completed successfully and will be discussed
  • clock

    16:00

    Protecting your innovative products and methods: How to patent RNA therapeutics

    Mark Chapman, Partner, Carpmaels & Ransford

  • Update on relevant developments at the European Patent Office (EPO) and elsewhere
  • Understanding the ‘problem-and-solution’ approach applied by the EPO
  • How to draft successful patent specifi cations for RNA therapeutics
  • clock

    16:40

    Chairman’s Closing Remarks and Close of Day Two


    CEO
    Silenseed
    Vice President RNA Biochemistry & Manufacturing
    BioNTech
    CSO
    KP Therapeutics Ltd
    CSO
    KP Therapeutics Ltd
    CEO
    Exicure Inc.
    VP RNA Formulation and Drug Developement
    BioNTech AG
    Head Preclinical R&D
    GSK
    Clinical Assessor, Biologicals & Biotechnology Unit
    MHRA
    Head of Drug Discovery, RNA Therapeutics Research
    Roche
    Partner
    Carpmaels & Ransford
    Senior Principal Scientist
    AstraZeneca
    Professor of Surgery, Imperial College, Co-founder MiNA therapeutics
    Imperial College London
    Senior Investigator
    Novartis Institutes for Biomedical Research
    Associate Prinicipal Scientist
    AstraZeneca
    VP, Pharmaceutical Development
    Quark Biotech Inc
    Managing Director
    Lipocalyx
    Director, Scinovo
    GSK

    Official Media Partner

    Official Publication

    Supporters

    RNA 2017 Preliminary Attendee List

    Download

    An Interview with Silenseed CEO, Amotz Shemi

    Download

    Media Partners


    Bio-ITWorld.com

    Official Media Partner
    http://www.Bio-ITWorld.com

    Weekly Update newsletter and News Bulletins cover the application of informatics, IT and computer science in biomedical research and drug discovery. As the life sciences become an increasingly quantitative discipline, Bio-IT World provides topical news coverage and analysis of cutting-edge technologies to handle the data deluge in petascale computing and the tools to deliver individualized medicine.

    Media Partners


    Int. J. of Bioinformatics Research and Applications

    Official Publication
    http://www.inderscience.com/ijbra

    Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.


    Int. J. of Data Mining and Bioinformatics

    Official Publication
    http://www.inderscience.com/ijdmb

    Mining bioinformatics data is an emerging area at the intersection between bioinformatics and data mining. The objective of IJDMB is to facilitate collaboration between data mining researchers and bioinformaticians by presenting cutting edge research topics and methodologies in the area of data mining for bioinformatics. This perspective acknowledges the inter-disciplinary nature of research in data mining and bioinformatics and provides a unified forum for researchers/practitioners/students/policy makers to share the latest research and developments in this fast growing multi-disciplinary research area.

    Media Partners


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    EIN News

    Supporters
    http://www.einnews.com

    EIN News is the world leader in industry focused online news monitoring. Thousands of leading companies, institutions and global professionals from business, industry, and government rely on EIN News as an indispensable resource. Our systems continuously scan the web, indexing news from thousands of worldwide sources. The news you need is then organized by advanced software systems managed by a team of professional news editors. Everything we do is focused on streamlining your news searches and research in order to save you time and money.


    British Pharmacological Society

    Supporters
    http://www.bps.ac.uk

    The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects. Clinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Labhoo

    Supporters
    http://www.labhoo.com



    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.